Cyprus has decided to buy 50,000 doses of Russian Sputnik V Covid-19 vaccine once it is cleared by the European Medicines Agency (EMA), government spokesman Kyriakos Koushos said on Tuesday.
He noted that the decision was made 15 days ago under a bilateral agreement with Russia, adding there is a possibility to buy more Sputnik V vaccine depending on the availability of other vaccines, the Xinhua news agency reported.
Two other European Union (EU) countries, Hungary and Slovakia, have already acquired the Russian vaccine.
Cyprus has placed orders for coronavirus vaccines collectively with all other EU countries with pharmaceutical companies with which the European Commission has struck commercial agreements on behalf of the member states.
So far, four vaccines -- Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson -- have been approved by the EMA.
Cyprus, along with a cluster of European countries including Germany, France, Spain and Italy, has suspended the use of AstraZeneca Covid-19 vaccine over blood clot concerns.
They described the move as a precautionary measure pending a decision by the EMA, which had greenlighted the use of the vaccine in the bloc on January 29.
A total of 263 candidate vaccines are still being developed worldwide -- 81 of them in clinical trials -- in countries including Germany, China, Russia, Britain, and the United States, according to latest information released by the World Health Organization.
The EMA said on March 4 that it had started a rolling review of the Sputnik V vaccine so as to be in a position to speed up any approval once the Russian side submits the marketing authorisation application for the vaccine.
Russian scientists have said that Sputnik V was almost 92 per cent effective against the coronavirus, based on peer-reviewed late-stage trial results published in the Lancet medical journal last month.
--IANS
int/rs
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU